Shukai T. Yuan

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness.

USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness.

Journal: Cell death & disease
Published: September 23, 2024

Effectiveness and safety of multimodal analgesia in open gastrostomy in patients with end-stage head and neck cancer

Effectiveness and safety of multimodal analgesia in open gastrostomy in patients with end-stage head and neck cancer

Journal: Zhonghua yi xue za zhi
Published: July 01, 2024

Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E-associated thyroid carcinoma.

Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E-associated thyroid carcinoma.

Journal: Clinical and translational medicine
Published: November 29, 2023

Correction: miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

Correction: miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

Journal: Oncogene
Published: November 18, 2023

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma.

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma.

Journal: Carcinogenesis
Published: April 28, 2023

Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Journal: Nature communications
Published: November 17, 2022

Correction: miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

Correction: miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

Journal: Oncogene
Published: February 05, 2022

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Journal: Nature communications
Published: May 31, 2021

miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma.

Journal: Oncogene
Published: February 08, 2021

Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma.

Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma.

Journal: Biomarkers in medicine
Published: December 21, 2020

Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.

Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.

Journal: Oncogene
Published: November 13, 2020

Author Correction: MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists.

Author Correction: MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists.

Journal: Nature communications
Published: October 16, 2020
Showing 1-12 of 18

Last Updated: 09/26/2026